Rasmussen et al. recently showed, in a pilot study in a galactosemia rat model (n = 7), that neonatal human GALT gene therapy with a AAV9 vector via tail vein injection led to GALT restoration in both liver and brain [54]. The gene discussed is GALT; the disease is galactosemia.